BioStem Technologies Stock (OTC:BSEM), Trade Ideas

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.

How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond 

Biotech

News

Health Care

General

BSEM

Florida-based BioStem Technologies, Inc. (OTCMKTS: BSEM) is a biotech company focused on developing and manufacturing structural-tissue allografts derived from perinatal tissues and intended for use as a protective covering for soft-tissue wounds. 

How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond

BioStem Reveals Plans For New Products, Expanded Sales And Manufacturing Capabilities At Dawson James Small Cap Growth Conference

Jason Matuszewski, CEO and co-founder of BioStem Technologies, Inc. (OTCMKTS: BSEM), presented at last year’s Dawson James Small Cap Growth Conference in October.

Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care  

Interview

Benzinga recently spoke to the CEO of BioStem Technologies, Inc. (OTCMKTS: BSEM) (“BioStem”), Jason Matuszewski, about his company’s mission and future. 

Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care

BIOSTEM TECHNOLOGIES NEW by BioStem Technologies, Inc.

BioStem Technologies Inc

Exponent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPO#NASDAQ">EXPO</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.47 by 25.53 percent. This is a 5.36 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $144.933 million which beat the analyst consensus estimate of $125.979 million by 15.05 percent. This is a 3.30 percent increase over sales of $140.309 million the same period last year.

Earnings

Earnings Beats

EXPO

Exponent Q1 2024 GAAP EPS $0.59 Beats $0.47 Estimate, Sales $144.933M Beat $125.979M Estimate

SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) reported quarterly earnings of $0.86 per share which beat the analyst consensus estimate of $0.74 by 16.22 percent. The company reported quarterly sales of $149.576 million which beat the analyst consensus estimate of $146.564 million by 2.05 percent. This is a 18.84 percent increase over sales of $125.868 million the same period last year.

SPSC

SPS Commerce Q1 2024 Adj EPS $0.86 Beats $0.74 Estimate, Sales $149.576M Beat $146.564M Estimate

Guidance

COLM

Columbia Sportswear Sees FY24 EPS $3.65-$4.05 (Prior $3.45-$3.85) vs $3.66 Est.

Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held in Stockholm, Sweden from July 17 - 20, 2024. &nbsp;
ASRS Annual Scientific Meeting Presentation Information
Title: Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study
Date / Time: Wednesday, July 17th, 2024 at 8:45am CEST
Session: Wet AMD Symposium 1
Presenter: Charles C. Wykoff, MD, PhD, FASRS, Director of Research, Retina Consultants of Texas; Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital
The presentation will be available on the <a href="https://www.globenewswire.com/Tracker?data=Md0wK3ixbFirVUkNX_UXVHtl-WiK6ncsdmIXkH8HmDct5FVlF9KS2xblDKACpA7OS_FuPn0aT-cSZ6--6ReuZTpebTiUXK6ADdd8I_EGJPs5uiB0mt0937Q2IIIxx3Kc">News and Publications</a> section of Adverum's website shortly after the presentation.

ADVM

Adverum Biotechnologies To Present LUNA 26-Week Phase 2 Interim Analysis At The ASRS Annual Scientific Meeting

Robert Half Says 'Q2 Earnings Guidance, Led By Protiviti, Anticipates Higher Sequential Earnings For The First Time In Seven Quarters'

Business First Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFST#NASDAQ">BFST</a>) reported quarterly earnings of $0.50 per share which missed the analyst consensus estimate of $0.57 by 12.28 percent. This is a 9.09 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $60.917 million which missed the analyst consensus estimate of $62.224 million by 2.10 percent. This is a 0.36 percent decrease over sales of $61.137 million the same period last year.

Earnings Misses

BFST

Business First Bancshares Q1 2024 Adj EPS $0.50 Misses $0.57 Estimate, Sales $60.917M Miss $62.224M Estimate

PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) reported quarterly losses of $(1.20) per share which beat the analyst consensus estimate of $(1.29) by 6.98 percent. The company reported quarterly sales of $210.118 million which beat the analyst consensus estimate of $169.703 million by 23.82 percent. This is a 4.66 percent decrease over sales of $220.382 million the same period last year.

PTCT

PTC Therapeutics Q1 2024 GAAP EPS $(1.20) Beats $(1.29) Estimate, Sales $210.118M Beat $169.703M Estimate

WIIM

Carlisle shares are trading higher after the company reported better-than-expected Q1 financial results.

Comfort Systems shares are trading higher after the company reported better-than-expected Q1 financial results and increased its quarterly dividend.

Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.35 by 5.71 percent. This is a 27.59 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $125.575 million which missed the analyst consensus estimate of $127.744 million by 1.70 percent. This is a 18.24 percent decrease over sales of $153.597 million the same period last year.

SBCF

Seacoast Banking Q1 2024 Adj EPS $0.37 Beats $0.35 Estimate, Sales $125.575M Miss $127.744M Estimate

Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.89 by 0.53 percent. The company reported quarterly sales of $789.000 million which beat the analyst consensus estimate of $772.298 million by 2.16 percent. This is a 6.48 percent increase over sales of $741.000 million the same period last year.

ALSN

Allison Transmission Q1 2024 GAAP EPS $1.90 Beats $1.89 Estimate, Sales $789.000M Beat $772.298M Estimate

Peoples Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFIS#NASDAQ">PFIS</a>) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.65 by 15.38 percent. This is a 47.12 percent decrease over earnings of $1.04 per share from the same period last year.

PFIS

Peoples Financial Servs Q1 EPS $0.55 Misses $0.65 Estimate

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) reported quarterly earnings of $2.69 per share which beat the analyst consensus estimate of $2.08 by 29.33 percent. The company reported quarterly sales of $1.537 billion which beat the analyst consensus estimate of $1.480 billion by 3.83 percent. This is a 30.81 percent increase over sales of $1.175 billion the same period last year.

Comfort Systems USA Q1 2024 GAAP EPS $2.69 Beats $2.08 Estimate, Sales $1.537B Beat $1.480B Estimate

AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.89 by 17.98 percent. This is a 10600 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $187.430 million which beat the analyst consensus estimate of $178.689 million by 4.89 percent. This is a 37.71 percent increase over sales of $136.100 million the same period last year.

APPF

AppFolio Q1 2024 Adj EPS $1.05 Beats $0.89 Estimate, Sales $187.430M Beat $178.689M Estimate

AllianceBernstein Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.71 by 2.82 percent. This is a 10.61 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $1.104 billion which beat the analyst consensus estimate of $902.782 million by 22.29 percent. This is a 7.81 percent increase over sales of $1.024 billion the same period last year.

AllianceBernstein Holding Q1 2024 Adj EPS $0.73 Beats $0.71 Estimate, Sales $1.104B Beat $902.782M Estimate

Weyerhaeuser Sees Q2 Earnings ~$10M Lower Than Q1 And Adj. EBITDA Comparable To Q1 Due To Timing And Mix Of Real Estate Sales

Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.89 by 0.53 percent. This is a 2.7 percent increase over earnings of $1.85 per share from the same period last year. The company reported quarterly sales of $789.00 million which beat the analyst consensus estimate of $772.30 million by 2.16 percent. This is a 6.48 percent increase over sales of $741.00 million the same period last year.

Allison Transmission Q1 EPS $1.90 Beats $1.89 Estimate, Sales $789.00M Beat $772.30M Estimate

Provident Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVBC#NASDAQ">PVBC</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.07 by 328.57 percent. This is a 130.77 percent increase over earnings of $0.13 per share from the same period last year.

PVBC

Provident Bancorp Q1 EPS $0.30 Beats $0.07 Estimate

WSFS Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>) reported quarterly earnings of $1.11 per share which beat the analyst consensus estimate of $1.07 by 3.74 percent. The company reported quarterly sales of $175.278 million which beat the analyst consensus estimate of $171.991 million by 1.91 percent. This is a 3.97 percent decrease over sales of $182.532 million the same period last year.

WSFS

WSFS Financial Q1 2024 Adj EPS $1.11 Beats $1.07 Estimate, Sales $175.278M Beat $171.991M Estimate

Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. The company reported quarterly sales of $1.796 billion which missed the analyst consensus estimate of $1.851 billion by 2.98 percent. This is a 4.52 percent decrease over sales of $1.881 billion the same period last year.